Dendreon News

The turmoil in the markets makes it too easy to justify selling any stock these days.

The stockpile of empty industrial facilities in metro Atlanta was hardly dented this year, despite some recent large transactions.

Dendreon Grasps for $400M, ZymoGenetics Cuts 52 Jobs, Calistoga Advances at ASH, & More Seattle-Area Life Sciences News LUKE TIMMERMAN XCONOMY I groused last week that Seattle biotech news was slow, so naturally, this week I got swamped.

Ridgewater Equity has recently begun technical & fundamental analysis of the following equities & their respective sectors, all reports can be accessed upon registration at 1. Exxon Mobil Corporation Sector: Basic Materials We also believe XOM has a balanced cash deployment and disciplined growth strategy to enhance the company overall... Want to ...

Dendreon said Thursday it has raised $356 million in net proceeds from selling 15 million shares of stock at $24.75 apiece.

Dendreon said Thursday it has raised $356 million in net proceeds from selling 15 million shares of stock at $24.75 apiece, and could tack on another $50 million if its investment bankers exercise an option for an additional 2.25 million shares.

Dendreon Corporation announced today that the underwriters of its previously announced public offering have exercised in full their option to purchase an additional 2,250,000 shares of common stock at the public offering price of $24.75 per share.

Dendreon has just nailed down one of the biggest biotech financings in the U.S. this year.

Biotechnology company Dendreon Corp. on Thursday named former Bayer executive Hans Bishop chief operating officer, making him responsible for leading the commercial launch of the potential prostate cancer treatment Provenge.

Dendreon Corporation today announced that Hans Bishop has joined the Company as chief operating officer, effective January 4, 2010.

According to the offering document , Dendreon expects to offer the stock at $27.07, and the resulting dilution per share to new investors will lower the price to $23.12. CEO Mitchell Gold didn't wait for the new stock to sell some of his shares, however.

Dendreon Corp. is looking to turn on the marketing and production engines in advance of the launch of its prostate cancer treatment, Provenge.

Biotechnology company Dendreon Corp. said Tuesday it will sell 15 million shares of common stock in a public offering and use the proceeds to fund investments in manufacturing facilities.

Recently, Dendreon Corp. announced that the U.S. Food and Drug Administration has accepted the amended Biologics License Application for Provenge, a therapeutic vaccine for the treatment of prostate cancer in men.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Biotechnology company Dendreon Corp. said Friday the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1. The drug is aimed at treating prostate cancer.

BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Wednesday, November 11th and determining how the stocks have performed after their last 12 quarterly, 6 quarterly and November earnings reports.

When a stock's share price is lower than the mercury in a North Dakota thermometer in February, investors tend to give it the cold shoulder.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 10/30/09, Gilead Sciences, Inc.

Dendreon Corporation today announced that it has completed the submission of the amended Biologics License Application for PROVENGE , the Company's lead investigational product, to the U.S. Food and Drug Administration .